


The GOLIATH project

Beating GOLIATH

GOLIATH (Generation Of Novel, Integrated and Internationally Harmonised Approaches for Testing Metabolism Disrupting Compounds) focusses on one of the most urgent regulatory needs in the field of endocrine disrupting chemicals (EDCs): the lack of methods for testing EDCs that disrupt metabolism. These chemicals, referred to as 'metabolism disrupting chemicals' (MDCs), are natural and anthropogenic substances that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes, and fatty liver. To help beat these metabolic disorders that have reached 'Goliathan' proportions worldwide, this project will develop new methods that span the entire adverse outcome pathway (AOP) spectrum. GOLIATH will generate the world's first integrated approach to testing and assessment (IATA) of MDCs.



The GOLIATH objectives

To improve understanding of the endocrine modes of action (MoA) of metabolism disrupting chemicals.

To develop assay candidates for testing MDCs based on confirmed MoA and biological effects in target tissues.

To select and develop assay candidates into (pre-) validated test methods in collaboration with OECD.

To develop an internationally harmonised, integrated approach to testing and assessment (IATA) of MDCs.

The GOLIATH consortium consists of world-leading experts in endocrinology, molecular biology, toxicology, chemistry, epidemiology, test method development, validation and chemical regulation. GOLIATH started in January 2019 and will run until December 2023.



Coordination and management

Project coordinator: Prof. Dr. Ir. Juliette Legler

Project deputy coordinator: Dr. Daniel Zalko

Project manager: Dr. Jorke Kamstra

Contact details

Juliette Legler

Institute for Risk Assessment Sciences, Utrecht University

Tel: +31 30 253 5217, Email: j.legler@uu.nl

